ArticleScientific reports2025
Mechanisms of diterpenes from Scutellaria Barbata D. Don against colorectal cancer via network pharmacology and experimental verification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulation of Antitumor Immunity and the Tumor Microenvironment byInternational journal of molecular sciences · 2026Article
- A Network Pharmacology Review of Plant-Derived Anticancer Compounds in Lung, Breast, Colorectal and Prostate Cancer.International journal of molecular sciences · 2026Review
- Catechin-Folate nano-niosomes from Osbeckia parvifolia Arn. induce apoptotic cell death in Ovarian cancer.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Annually, colorectal cancer (CRC) claims nearly 700,000 lives globally, thereby positioning it among the most lethal diseases worldwide. Scutellaria barbata D. Don (BZL), acknowledged for its demonstrated efficacy, is currently undergoing investigation as a potential therapeutic recourse for this formidable cancer. Seven diterpenes were tested, leading to identification of BZL-5 as the most promising compound. It exhibits activity against colorectal cancer via a number of different targets and mechanisms. Its ability to combat oxidative stress, inflammation, and apoptosis is believed to be the mechanism of action. With respect to BZL-5, HIF1A exhibits the highest binding affinity, and HIF-1 may be a crucial component in the pharmacological pathway. Experimental verification in vitro was explored the possible mechanism of BZL against colorectal cancer using a thorough analytical approach. The overarching objectives of this investigation are to demystify the underlying molecular mechanism and identify potential targets instrumental in the development of novel colorectal cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.